Manufacturer
INTAS PHARMACEUTICALS LTD
Contents
Exemestane
Indication
Adjuvant treatment of postmenopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3 yr tamoxifen & switched to exemestane for completion of a total of 5 consecutive yr adjuvant hormonal therapy. Advanced breast cancer in women w/ natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy. Postmenopausal women w/ advanced breast cancer whose disease has progressed following multiple hormonal therapies.
Instruction
Should be taken with food.
Drug interaction
Negated pharmacologic action w/ oestrogen-containing products.
Malaysia
